DGAP-Adhoc: biolitec AG achieved consolidated revenue of

biolitec AG / Quarter Results

28.11.2008 

Release of a Adhoc News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------

Jena, November 28, 2008  biolitec AG, Jena, listed in the Prime Standard
of the Frankfurt stock exchange (ISIN DE0005213409) posted a consolidated
revenue of Euro 7.4 million for the first quarter of the fiscal year
2008/2009 The revenue slightly exceeded the turnover in Q4 of 07/08
indicating bottoming-out, as the summer quarter (Q1) is usually the
companys lowest. Q1 of 07/08 included substantial shipments to a major US
mobilizer, compared to that revenue was 20% lower.
The gross profit amounted to Euro 5.3 million (last fiscal year: Euro 6.6
million) and EBIT amounted to Euro 0.5 million (previous year: Euro 1.7
million). R&D expenditures for the first three months of the fiscal year
2008/2009 of Euro 1.1 million (14% of sales) remained at a high level to
ensure the groups long term growth and profitability. Net income amounted
to Euro 0.6 million (previous year: Euro 1.4 million) despite the
continuous high R&D investments.

The revenue posted by the laser segment of Euro 2.4 million was lower than
in the prior year mainly due to the market decline in the USA, in general
and by the big order shipments in Q1 07/08. The fiber optics and laser
probes segment contributed  4.6 million to the groups total revenue.
Mainstays of sales are the LIFE BPH laser treatment and the Endoluminal
Laser Treatment of Veins (ELVeS).
Foscan®, our head and neck cancer drug, received a major boost due to
finalizing the deal with Bracco. It is now reimbursed unconditionally in
Italy and has recently received Dutch reimbursement, France is expected to
follow.
biolitec AGs major revenues were again generated in Europe and North
America. With Euro 2.7 million, sales in North America were 43% lower than
previous years sales contributing 37% of total sales. European sales
amounted to Euro 3.8 million (previous year: Euro 4.0 million). ROW
increased 87% to  0.9 million indicating the companies international
expansion starts to pay off. biolitec AG expects sales growth to pick up
during the fiscal year. Staff levels were reduced and will result in
reduced inventories and working capital in the coming quarters.
DGAP 28.11.2008 
---------------------------------------------------------------------------
Language:     English
Issuer:       biolitec AG
              Winzerlaer Straße 2a
              07745 Jena
              Deutschland
Phone:        +49 (0)3641 5 08-5 50
Fax:          +49 (0)3641 5 08-5 99
E-mail:       info@biolitec.de
Internet:     www.biolitec.de
ISIN:         DE0005213409
WKN:          521340
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Stuttgart, München, Hamburg, Düsseldorf
End of News                                     DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: biolitec AG achieved consolidated revenue of Euro 7.4 million for the first three months of the fiscal year 2008/2009 - EBIT amounts to Euro 0.5 million
